Equities Analysts Offer Predictions for Immunic Q2 Earnings

Immunic, Inc. (NASDAQ:IMUX) – Equities researchers at HC Wainwright dropped their Q2 2026 earnings per share estimates for Immunic in a research report issued to clients and investors on Thursday, May 14th. HC Wainwright analyst M. Caufield now forecasts that the company will earn ($2.41) per share for the quarter, down from their prior estimate of ($2.06). HC Wainwright has a “Buy” rating and a $22.00 price target on the stock. The consensus estimate for Immunic’s current full-year earnings is ($3.38) per share. HC Wainwright also issued estimates for Immunic’s Q3 2026 earnings at ($2.21) EPS, Q4 2026 earnings at ($2.03) EPS, FY2026 earnings at ($7.02) EPS, FY2027 earnings at ($9.05) EPS, FY2028 earnings at ($5.88) EPS, FY2029 earnings at ($4.51) EPS and FY2030 earnings at ($2.92) EPS.

Immunic (NASDAQ:IMUX) last announced its quarterly earnings results on Wednesday, May 13th. The company reported ($1.08) EPS for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.37).

Several other research firms have also issued reports on IMUX. Guggenheim initiated coverage on Immunic in a research note on Tuesday, March 24th. They issued a “buy” rating and a $70.00 price objective for the company. raised Immunic to a “strong-buy” rating in a research note on Tuesday, February 3rd. Stifel Nicolaus set a $25.00 price objective on Immunic and gave the company a “buy” rating in a research note on Thursday, April 16th. Lifesci Capital raised Immunic to a “strong-buy” rating in a research note on Monday, May 4th. Finally, D. Boral Capital lowered Immunic from a “buy” rating to a “hold” rating in a research note on Wednesday, April 15th. Three analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Immunic presently has an average rating of “Buy” and a consensus target price of $50.86.

Immunic Trading Down 3.5%

Shares of Immunic stock opened at $11.66 on Tuesday. The firm has a market cap of $158.81 million, a PE ratio of -2.09 and a beta of 1.20. Immunic has a 12 month low of $5.06 and a 12 month high of $15.10. The stock has a 50 day moving average of $11.45 and a 200 day moving average of $8.66.

Institutional Investors Weigh In On Immunic

Several hedge funds and other institutional investors have recently modified their holdings of the business. ADAR1 Capital Management LLC purchased a new stake in shares of Immunic in the first quarter worth approximately $33,000. Qube Research & Technologies Ltd purchased a new stake in shares of Immunic in the third quarter worth approximately $29,000. Focus Partners Wealth raised its holdings in shares of Immunic by 1.5% in the third quarter. Focus Partners Wealth now owns 2,581,587 shares of the company’s stock worth $2,276,000 after buying an additional 39,063 shares during the period. Two Sigma Investments LP purchased a new stake in shares of Immunic in the third quarter worth approximately $52,000. Finally, Squarepoint Ops LLC raised its holdings in shares of Immunic by 29.9% in the fourth quarter. Squarepoint Ops LLC now owns 352,875 shares of the company’s stock worth $188,000 after buying an additional 81,301 shares during the period. 51.82% of the stock is currently owned by hedge funds and other institutional investors.

Trending Headlines about Immunic

Here are the key news stories impacting Immunic this week:

• Positive Sentiment: Immunic appointed veteran biopharmaceutical executive Michael W. Bonney as Chair of the Board, a move that may be viewed favorably because of his deep commercialization and leadership experience in multiple sclerosis and biotech. Immunic Appoints Seasoned Biopharmaceutical Executive Michael W. Bonney as Chair of the Board of Directors
• Neutral Sentiment: Multiple brokerage notes reiterated bullish ratings on Immunic, including HC Wainwright’s Buy rating and $22 price target, which suggests continued long-term optimism despite near-term risk.
• Negative Sentiment: HC Wainwright cut earnings estimates across several future periods, signaling expectations for larger losses than previously modeled. The firm reduced its FY2026 EPS estimate to ($7.02) from ($2.61), FY2027 to ($9.05) from ($6.01), FY2028 to ($5.88) from ($3.66), FY2029 to ($4.51) from ($2.36), and FY2030 to ($2.92) from ($1.08).
• Negative Sentiment: The analyst also lowered quarterly EPS forecasts for Q2 2026, Q3 2026, and Q4 2026, reinforcing concerns that Immunic may burn cash for longer than expected before reaching profitability.

About Immunic

Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company’s research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.

Immunic’s lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn’s disease and relapsing multiple sclerosis.